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"While this research continues, however, we have a responsibility to ensure that women with advanced ovarian cancer who are candidates for IP therapy benefit from this treatment advance associated with such a remarkable improvement in overall survival [1] ." This statement was printed in the January, 2006 National Cancer Institute's (NCI), Division of Cancer Treatment and Diagnosis announcement concerning the survival benefits of intraperitoneal chemotherapy for stage III ovarian cancer [1, 2] . Despite the efforts of the NCI, the Gynecologic Oncology Group (GOG), the Society for Gynecologic Oncology (SGO), and the American Society of Clinical Oncology (ASCO) to educate gynecologic and medical oncologists concerning the remarkable efficacy of intraperitoneal chemotherapy and the way it should be administered, the majority of women with stage III, optimally debulked disease, are not being offered or treated with intraperitoneal chemotherapy [3] .
This lack of widespread use of intraperitoneal (IP) chemotherapy among today's oncologists has at its roots many causes, some more understandable than others. Certainly, the toxicities of early IP therapy that required intensive support and multiple interventions, coupled with catheter-related complications, dampened the initial enthusiasm. These critical, early negative experiences are understandably hard to overcome on an emotional level. However, our knowledge and skill have grown over three decades of IP therapy clinical trial research, and many of these challenges have now been overcome. Furthermore, the positive results of multiple randomized Phase III, NCI funded, nationally recognized, cooperative group clinical trials should by now have achieved standard of practice [4] [5] [6] . In a 2002 editorial in the Journal of Clinical Oncology, Drs. David Alberts, Maurie Markman, Deborah Armstrong, Mace Rothenberg, Franco Muggia, and Stephen Howell stated, "We cannot think of any other setting in oncology where the results of three positive phase III trials have not led to widespread adoption of the superior therapy. The time has come for IP chemotherapy to move beyond the setting of clinical trials and into the standard treatment armamentarium for women with optimally debulked stage III ovarian cancer. We owe our patients nothing less [7] ." That being said, our task is to look forward, not backward, in terms of how we can prolong the lives of these extremely courageous women with advanced ovarian cancer who fight everyday to stay alive. D.S. Alberts (*) and S.K. Chambers Director, Arizona Cancer Center, University of Arizona, Tucson, AZ 85724-5024, USA e-mail: dalberts@azcc.arizona.edu While evaluating the chronology of treatment advances for advanced ovarian cancer, there have been a few seminal events during the last 40 years, as shown in Fig. 1.1 and described below.
1. Documentation that total abdominal hysterectomy with bilateral salpingo-oopherectomy (TAH-BSO), omentectomy, and debulking of tumor down to less than 1 cm sized residual in the intraperitoneal space are associated with improved survival in patients with stage III epithelial ovarian cancer [8] [9] [10] . 2. Identification of intravenous cisplatin as a potentially curative and tolerable drug in the treatment of advanced epithelial ovarian cancer [11, 12] . 3. Development of the intravenous combination of cisplatin plus paclitaxel to prolong survival in patients with suboptimally resected stage III and IV ovarian cancer [13] . 4. Development of intravenous (IV) carboplatin and the combination of carboplatin plus IV paclitaxel as a less toxic but equally effective alternative to IV cisplatin and the combination of cisplatin plus paclitaxel [14] [15] [16] . 5. Documentation in phase III clinical trials that intraperitoneal cisplatin, as compared to intravenous cisplatin with or without intravenous paclitaxel, prolongs survival in patients with stage III optimally resected ovarian cancer [4, 6] . 6. Documentation that the addition of intraperitoneal paclitaxel to intraperitoneal cisplatin may further prolong progression-free survival and overall survival to more than 5 years, in comparison to intravenous platinum/taxane regimens [5, 17] . 7. Evidence from phase II trials that intravenous bevacizumab is associated with unusually high objective response rates and enhanced progression-free survival in patients with platinum-resistant, recurrent ovarian cancer [18] [19] [20] [21] . Although phase III trials of bevacizumab in patients with ovarian cancer are yet to be completed, they likely will document a major impact on patient survival. 
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Single Alkylating Agent (12 mo.) * [27] Non-Platinum Drug Combinations (15 mo.) * [27] IV Cisplatin +/−Alkylating Agent (20 mo.) * [8, 11, 12, 28] IV Carboplatin +/− Alkylating Agent (20 mo.) * [14] IV Cisplatin IV Paclitaxel (38 mo.) * [13] IP Cisplatin IV Paclitaxel (63 mo.) [6] IP Cisplatin IV/IP Paclitaxel (66 mo.) [5] IP Cisplatin IV Cyclophosphamide (49 mo.) [4] IV Carboplatin IV Paclitaxel (57 mo.) [16] * Suboptimally debulked, stages II/IV disease There are multiple erroneous concepts that continue to mitigate against the universal incorporation of intraperitoneal chemotherapy administration for stage III, optimally resected ovarian cancer. All of these will be addressed in-depth in the following chapters of this text, which are authored by highly experienced investigators in this field. We believe that it is important to correct the misconceptions that continue to hinder treatment progress as follows: Misconception #1: Intraperitoneal cisplatin chemotherapy inherently is too toxic for standard of care treatment. In at least one head-to-head comparison of IP to IV cisplatin at 100 mg/m 2 , the patients treated in the IP phase III trial arm experienced significantly less leukopenia, neutropenia, tinnitus, clinical hearing loss, and neuropathic pain [4] . Only abdominal pain of relatively short duration (related to the mandated 2L IP fluid volumes) was more common in the IP group. In GOG 0172, there was clearly more acute toxicity in the IP trial arm; however, the IP-treated patients received 33% more cisplatin than did those on the IV trial arm [5] . Furthermore, IV paclitaxel in the IP-treatment arm was administered as a 24-h infusion (as compared to a 3-h infusion in the IV-treatment arm). These facts in large part explain the imbalanced acute toxicities of the IP therapy in this study. An in-depth quality of life evaluation using the Functional Assessment of Cancer Therapy (FACT-O) instrument revealed equivalent scores for the IV and IP-treated patient populations 1 year after planned chemotherapy completion [22] . Thus there is hardly a cogent argument to indict the GOG 0172 IP experimental arm as "too toxic for standard usage," especially in light of the documented 16-month increase in median survival associated with its use. Please refer to book Chap. 4 for in-depth discussions of these issues.
Misconception #2: The procedure for intraperitoneal chemotherapy is technically difficult, time-consuming, expensive, and requires in-patient care. The techniques involved in the administration of intraperitoneal cisplatin, paclitaxel, and several other anticancer agents (e.g., carboplatin, fluorodeoxyuridine, interferon-alpha) have been greatly improved over more than three decades. With laparoscopic placement of an intravenous type infusion port (as opposed to the commercially available intraperitoneal type infusion ports), the administration of intraperitoneal drugs has become a routine outpatient procedure, as described in detail in Chaps. 3,6, and 8. Granted, in general, medical oncology fellowship training in this disease area has traditionally been weak or nonexistent, leading to the relative lack of interactions between medical oncologists and gynecologic oncologists in the outpatient setting. This gap in training has further compounded the steep learning curve for optimal intraperitoneal therapy management. The NCI's Division of Cancer Treatment and Diagnosis sponsored a Clinical Announcement supporting intraperitoneal therapy and greatly heightened educational efforts that are required in fellowship programs, NCIdesignated Comprehensive and Clinical Cancer Centers, as well as Community Clinical Oncology Program sites, concerning all aspects of the outpatient management in the setting of intraperitoneal therapy [1, 2] . In the Women's Cancers Pavilion at the Arizona Cancer Center, we have had a long-term interdisciplinary clinical research effort, led by Dr. Setsuko K. Chambers, Director of Gynecologic Oncology, and her gynecologic oncology colleagues, Drs. Kenneth Hatch and Janiel Cragun and medical oncologist colleagues (Drs. Ana Maria Lopez, Michael Bookman, and David Alberts) and multiple, specially trained research and clinical nursing staff. Without a "buy-in" from medical oncology and gynecologic oncology training programs to develop interdisciplinary participation in educational forums, ovarian cancer patients likely will be denied potentially lifesaving therapy. See Chaps. 5, 6, 7, and 8 for in-depth discussions of these issues.
Misconception #3: The designs of the three positive phase III trials comparing IP to IV therapy were flawed. According to the Center For Evidence Based Medicine, University of Oxford guidelines, the most convincing level of clinical trials evidence is a metaanalysis of well-designed, adequately powered, phase III studies [23] . Presently, there are three published metaanalyses, all of which have documented a pooled overall survival benefit to IP regimens (i.e., HR 0.79, 95% CI: 0.70-0.89) [1, 2, 24, 25] . The NCI-sponsored metaanalysis led to a rare NCI Clinical Announcement in January, 2006 [2] . Basically, all women with stage III, optimally debulked ovarian cancer should be educated about the potential benefits of cisplatin-based intraperitoneal therapy.
Virtually, all adequately powered phase III cancer clinical trials have design flaws, some large and some small. Ultimately, what counts is consistency in the results, as documented in the three IP vs. IV trial metaanalyses that have been published in Gynecologic Oncology, the Cochrane Data Base of Systematic Reviews, and International Journal of Gynecologic Cancer [1, 24, 25] . In Chap. 4 of this text there is a detailed discussion about the controversies involved in the pivotal phase III trial results (e.g., see Table 4 .6).
Misconception 4: The future of intraperitoneal therapy is poor in the era of molecularly targeted drug development. Clearly, the landscape for molecularly targeted drug development for advanced ovarian cancer is expanding rapidly. It is extremely likely that the primary treatment of advanced ovarian cancer, whether optimally or suboptimally debulked, will change as the survival data from research protocol GOG 0218 (a phase III trial of IV carboplatin plus paclitaxel with or without bevacizumab) become available. The results of multiple phase II trials of bevacizumab in mainly platinum-resistant, recurrent disease have documented objective response rates of 15-25% (and 30-40% of patients progression-free at 6 months) with excellent tolerance [18, 21] . The initial concerns about relatively high rates of bowel perforation have diminished as larger safety analyses have been published [18, 21] . Of extreme relevance to both the continuing evaluation of intraperitoneal therapy and the role of intravenous bevacizumab is the activation of GOG 0252 (in the GOG), which will compare IV carboplatin plus IV paclitaxel (i.e., weekly regimen) to IP carboplatin plus weekly IV paclitaxel or IP cisplatin plus IV/IP paclitaxel. IV bevacizumab has been added to all three study arms, assuming that GOG 0218 will document a survival advantage for the bevacizumab in the phase III trial design [18, 26] (Walker 2009, Personal communication concerning Gynecologic Oncology Group protocol GOG 0252).
Obviously, bevacizumab has a major head start over other targeted agents for the management of advanced ovarian cancer; however, numerous other targeted agents are in earlier stages of development as discussed in Chaps. 7 and 9 of this text. With the explosion of drug development for advanced ovarian cancer, it will become more difficult to identify large numbers of eligible patient participants for any future, individual trial, unless we invite international research participation.
Misconception #5: There is no room for innovation to further improve intraperitoneal chemotherapy for advanced ovarian cancer. As discussed in Chaps. 8, 9, 10, and 11, there 1 Introduction is tremendous opportunity for innovation in IP drug administration (e.g., selection of intraperitoneal infusion solutions and improvement in IP drug delivery technology), the testing of novel cytotoxic drugs and biologic agents, further development of hyperthermic, intraoperative cytotoxic drug perfusions, and for improvement in supportive care procedures. In fact, we are just at the dawn of the era of the universal establishment of intraperitoneal therapy for advanced, surgically debulked ovarian cancer; however, for IP administration to be successful, it will take much greater outreach educational efforts at all levels of participants, including gynecologic oncologists, medical oncologists, oncology nurses, pharmacologists, and pharmacists, as well as the patients themselves. Ultimately, the national cooperative clinical trials groups, including the GOG and the Southwest Oncology Group (SWOG), with considerably more support from the NCI, must become dedicated in advancing this burgeoning field of drug discovery and research translation. Our patients deserve no less! 
Trials that Define Primary Treatment
Current optimal management of advanced-stage ovarian cancer includes maximal cytoreductive surgery and a program of chemotherapy with carboplatin and paclitaxel, generally administered for six cycles. While the chemotherapy has been validated by phase III trials, there are areas of controversy, as well as gaps in knowledge, contributing to acceptable variations in clinical practice as applied to individual patients. A number of strategies have been evaluated with the goal of improving treatment outcomes, including dose intensity, maintenance-consolidation, schedule variations, intraperitoneal administration, regional hyperthermia, and incorporation of additional cytotoxic agents. Many of the phase III trials that have defined current treatment options are summarized in Table 2 .1.
Platinum compounds remain dominant as the most active cytotoxic agents currently utilized in the treatment of ovarian cancer. Over the last 30 years, the therapeutic ratio of platinum-based primary chemotherapy has been improved through the development of less toxic analogs (carboplatin) and the determination of optimal dose, schedule, sequence, and duration of treatment [1] [2] [3] [4] . In general, the administration of higher doses of chemotherapy with hematopoietic support, or extended administration of multiple cycles of chemotherapy (beyond six cycles), has not improved long-term outcomes, and these strategies carry an increased risk of serious cumulative toxicity [5] [6] [7] . Improved median survival with paclitaxel and platinum [8] [9] [10] "Platelet-sparing effect" in combination with carboplatin raises questions of drug-drug antagonism [28] Sequential single-agent therapy appropriate for some patients [12, 13] Optimal scheduling Improved therapeutic ratio (phase I-II) associated with weekly therapy in recurrent disease [16, 17] Improved progression-free survival with dose-dense weekly paclitaxel in combination with carboplatin as primary treatment [18] Docetaxel vs. paclitaxel Different toxicity profile without improved long-term outcomes [15] Intraperitoneal therapy 
Optimal Integration of Taxanes
Mature results from Gynecologic Oncology Group (GOG) protocol GOG 0111 and the National Cancer Institute of Canada (NCIC) and European Organization for Research and Treatment of Cancer (EORTC) trial, protocol OV10, established the superiority of cisplatin plus paclitaxel as compared to cisplatin plus cyclophosphamide [8] [9] [10] . In addition, GOG 0158 and Abeitsgemeinschaft Gynäkologische Onkologie-Ovarialkarzinom (Gynecologic Oncology Ovarian Cancer Study Group, AGO-OVAR) studies established that carboplatin plus paclitaxel was at least as effective as cisplatin plus paclitaxel [3, 4] . Based on these findings, the Gynecologic Cancer InterGroup (GCIG) published consensus guidelines favoring carboplatin and paclitaxel as the preferred comparator arm for clinical trials [11] . However, the GOG 0132 and International Collaborative Ovarian Neoplasm (ICON3) trials have suggested that sequential therapy with platinum followed by paclitaxel at progression can achieve equivalent long-term outcomes for some patients, supporting a role for individualized selection criteria while reinforcing the primary activity of platinum compounds [12, 13] . Taxanes have clearly emerged as the second most important class of cytotoxic agents. In addition to data from front-line trials, a phase III trial in the setting of platinum-sensitive recurrent disease, ICON4, also demonstrated superiority of a combination of carboplatin and paclitaxel compared to carboplatin regimens without paclitaxel, but without directly addressing the role of sequential single-agent therapy [14] .
Substitution of docetaxel is an acceptable alternative to paclitaxel in the front-line setting with a reduced risk of neuropathy and hypersensitivity, but with an increased risk of dose-limiting hematologic toxicity, based on a phase III trial [15] . In spite of interesting molecular pharmacodynamics, there are no data to indicate clinical superiority of docetaxel when compared to paclitaxel in the management of newly diagnosed or recurrent epithelial ovarian cancer.
With paclitaxel, longer infusions (³24 h) increase mucosal and bone marrow toxicity, but without improved efficacy. Shorter infusions (<3 h) are generally better-tolerated from a hematologic perspective, although higher individual doses can increase the risk of arthralgia-myalgia and neuropathy. Weekly scheduling permits higher cumulative dose delivery, while avoiding hematologic toxicity and alopecia, and has demonstrated consistent activity in patients who have recurred within 6 months of primary therapy with conventional carboplatin and paclitaxel [16, 17] .
The Japanese Gynecologic Oncology Group (JGOG) conducted a phase III trial in women with newly diagnosed advanced-stage ovarian cancer, demonstrating superiority of weekly dose-dense paclitaxel in combination with standard doses of carboplatin compared to standard scheduling of the same drugs [18] . This is an important finding, illustrating the need to carefully examine how we use standard agents, as well as strategies to incorporate new agents. Ongoing phase III trials through GOG and other groups aim to extend the JGOG findings, including integration with intraperitoneal chemotherapy and bevacizumab.
Integration of a Third Cytotoxic Agent
A number of nonplatinum cytotoxic agents have well-defined activity in the management of recurrent disease, including topotecan, pegylated liposomal doxorubicin (PLD), prolonged oral etoposide, and gemcitabine. Each of these agents has a unique molecular target, mechanism of action, and pathways of resistance. In view of the central role of platinum, there has been particular interest in the incorporation of agents that may
